PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
Phase 2
Completed
- Conditions
- Reduction in Severity of Skin Scarring
- Interventions
- Drug: EXC 001 (currently called PF-06473871)
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01494922
- Locations
- πΊπΈ
Altus Research, Lake Worth, Florida, United States
πΊπΈNorthwestern University,Division of Plastic Surgery, Chicago, Illinois, United States
πΊπΈConnall Consmetic Surgery, Tualatin, Oregon, United States
A Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate
Phase 4
Withdrawn
- Conditions
- Diarrhoea
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Idoform Plus
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2013-09-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01491659
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
Phase 1
Terminated
- Conditions
- Type 2 Diabetic Nephropathy
- Interventions
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT01488877
- Locations
- πΊπΈ
Pfizer Investigational Site, New York, New York, United States
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: CP-690,550 or PlaceboDrug: Placebo
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 148
- Registration Number
- NCT01484561
- Locations
- πͺπΈ
Pfizer Investigational Site, Sevilla, Spain
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
Completed
- Conditions
- Non-Melanoma Skin Carcinoma
- Interventions
- Other: no voriconazole (Vfend)
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 467
- Registration Number
- NCT01480219
A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT01479647
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 345
- Registration Number
- NCT01475461
- Locations
- πΊπΈ
Anaheim Clinical Trials, Anaheim, California, United States
πΊπΈNational Research Institute, Los Angeles, California, United States
πΊπΈPriMed Clinical Research, Kettering, Ohio, United States
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01475383
- Locations
- πΊπΈ
Pfizer Investigational Site, Manhasset, New York, United States
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT01474941
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01473043
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada